Under the terms of the contract, Absolu will immediately begin work on developing the branding of the new MSN-2 medical device; including the brand name, visual identity (logo, packaging, artwork), and marketing language around the new product. In Phase Two of the contract, Absolu will develop a secure transactional website, which will allow ETST to sell the device via the web to customers anywhere in the world. The additional security concern will help ensure customers’ identities and personal information are protected. In Phase Three, the agency will deliver a Communications and Marketing Action Plan for the rollout of the new device. They will also manage the launch of the MSN-2, and the accompanying publicity.

“We are very proud to be working with Absolu on the pre-launch and launch of the MSN-2, and we hope to continue our relationship as we roll out our new nutrition and nutraceutical products in the coming year,” said Chief Executive Officer and Chief Scientific Officer Michel Aubé, PhD.

The MSN-2 medical device is a new product, which will allow women to manage their own testing for Sexually Transmitted Diseases. Using MSN-2, women can collect their own cell sample in the privacy of their home and send it anonymously to a dedicated laboratory for testing. The MSN-2 is slated to launch during Q1 2018, and has been a key component of the company-wide women’s health initiatives.

ETST’s President, Director, and COO, Nickolas S. Tabraue concluded, “We expect to sign an agreement within three weeks for an exclusive distribution of a new medical devices manufacture by our future partner in two countries. This is an important step, as the release of our own MSN-2 medical device will be in the same timeline as this second medical device. We will have two medical devices ready to market overseas first, and in North America shortly after. This is an important step, as releasing our medical device in the North American markets will likely be delayed by several months, due to the complex nature of the regulatory environment in the US and Canada. We plan on updating our shareholders as further progress and development occurs.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. T To learn more please visit: www.earthsciencetech.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. To learn more please visit: www.Cannabisthera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties. Website coming soon: www.kannabidioidinc.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Newswire Distribution Network & Management

About Us

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.